An Overview of Psoriasis

Therapy of Moderate-to-Severe Psoriasis, Second Edition, Revised and Expanded

Volumn , Issue , 2003, Pages 1-28

  Weinstein, Gerald D ^a   Menter, M Alan ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 32644471614     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b14220-5     Document Type: Chapter

References (41)

1. Drake LA, Ceilley RI, Cornelison RL, Dinehart SM, Dorner W, Goltz RW, Graham GF, Hordinsky MK, Lewis CW, Pariser DM, et al. Guidelines of care for psoriasis. J Am Acad Dermatol 1993; 28:632–637.
2. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, Koo J, Krueger JG, Lebwohl M, Lowe N, Menter A, Morison WL, Prystowsky JH, Shupack JL, Taylor JR, Weinstein GD, Barton TL, Rolstad T, Day RM. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000; 43:281–285.
3. Ferrandiz C, Pujol RM, Garcia-Patos V, Bordas X, Smandia, JA. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol 2002; 46:867–873.
4. Henseler T, Christophers E. Psoriasis of early and late onset: characteristics of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13:450–456.
5. Farber EM, Nall ML, Epidemiology: Natural history and genetics. In: Roenigk HHJ, Maibach HI, eds. Psoriasis, 2nd ed. New York: Marcel Dekker, 1991:209–253.
6. Farber EM, Nall ML, Genetics of psoriasis: twin study. In: Farber EM, Cox AJ, eds. Psoriasis—Proceedings of the International Symposium. Stanford, CA: Stanford University Press, 1971:7–13.
7. Tomfohrde J, Silverman A, Barnes R, Fernandez-Vina MA, Young M, Lory D, Morris L, Wuepper KD, Stastny P, Menter A, Bowcock A. Gene for familial psoriasis susceptibility mapped to the distal end of chromosome 17q. Science 1994; 264:1141–1145.
8. Nair RP, Henseler T, Jenisch S, Stuart P, Bichakjiam CK, Lenk W, Westpahl, Guo SW, Christophers E, Voorhees JJ, Elder JT. Evidence for two psoriasis susceptibility loci (HLA and 17q) in two novel candidate regions (16q and 20p) by genome-wide scan. Hum Mol Genet 1997; 6:1349–1356.
9. Capon F, Novelli G, Semperini S, Clementi M, Nudo M, Vultaggio P, Mazzanti C, Gobello T, Botta A, Fabrizi G, Dallapiccola B. Searching for psoriasis susceptibility genes in italy: genome scan and evidence for a new locus to chromosome 1q. J Invest Dermatol 1999; 112:32–35.
10. Bhalerao J, Bowcock A. The genetics of psoriasis: a complex disorder of the skin and immune system. Hum Mol Genet 1999; 7:1537–1545.
11. Beck S, Geraghty D, Inoko H. Complete sequence and gene map of a human major histocompatibility complex. Macher 1999; 401:921–923.
12. Allen MH, Veal C, Faassen A, Powis SH, Vaughan RW, Trembath RC, Barker JN. A non-HLA gene within the MHC in psoriasis. Lancet 1999; 353:1589–1590.
13. Nair RP, Stuart P, Henseler T, Jenisch S, Chia NV, Westphal E, Schork NJ, Kim J, Lim HW, Christophers E, Voorhees JJ, Elder JT. Localization of psoriasis susceptibility locus. PSORS 1 to a 60 kilobase interval telomeric 2 HLA-C. Am J Hum Genet 2000; 66:1833–1844.
14. Burden AD. Identifying a gene for psoriasis on chromosome 6 (Psors1). Br J Dermatol 2000; 143:238–241.
15. Lin XR. Psoriasis in China. J Dermatol 1993; 20:746–755.
16. Van Scott EJ, Ekel TM. Kinetics of hyperplasia in psoriasis. Arch Dermatol 88:373–381.
17. Weinstein GD, Van Scott EJ. Turnover time of human normal and psoriatic epidermis by autoradiographic analysis. J Invest Dermatol 1966; 45:561–567.
18. Weinstein GD, McCullough JM, Ross PA. Cell kinetic basis for the pathophysiology of psoriasis. J Invest Dermatol 1985; 85:579–583.
19. Jeffes EWB III, McCullough JL, Pittelkow MR, McCormick A, Almanzor J, Lieu G, Dang M, Voss J, Schlotzhauer A, Weinstein GD. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Derm 1995; 104:183–188.
20. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch. Dermatol 1999; 135:1104–1110.
21. Gottlieb AB. Psoriasis: immunopathology and immunomodulation. Derm Clinics 2001; 19:649–657.
22. Boyd AS, Menter A. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol 1989; 985–991.
23. Gladman DD, Farewell VT, Nadeau C. Clinical indications of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 1995; 22:675–679.
24. Newbold PCH. Pruritus in Psoriasis. In: Farber EM, Cox AJ, eds. Proceedings of the Second International Symposium. New York: Yorke Medical Books, 1977: 334–336.
25. Yosip OV, Itca G, Goon A, Wee J. The Prevalence and Clinical Characteristics of Pruritus Among Patients with extensive Psoriasis. Br J Dermatol 2000; 143:969–973.
26. Eyre RW, Krueger GG, Response to injury of skin involved and uninvolved with psoriasis, and its relation to disease activity: Koebner and ‘reverse’ Koebner reactions. Br J Dermatol 1982 Feb; 106:153–159.
27. Kaplan MH, Sadick N, McNutt NS, Dermatologic findings and manifestations of acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol 1987; 16:485–506.
28. Able EA, DiCicco LM, Orenberg EK, Fraki JE, Farber EM. Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986; 1007–1022.
29. Gilleaudeau P, Vallat VP, Carter DM. Arniotensim converting enzyme inhibitor as possible exacerbating drugs in psoriasis. J Am Acad Dermatol 1993; 28:490–492.
30. Baker H, Ryan T. Generalized pustular psoriasis: a clinical and epidemiological study of 103 cases. Br J Dermatol 1968; 80:771–773.
31. Liem W, McCullough JL, Weinstein GD. Effectiveness of topical therapy for psoriasis: results of a national survey. Cutis 1993; 55:306–310.
32. Al-Shevarden S, Feldman S. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 42:796–802.
33. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993; 28:454–459.
34. Sander HM, Morris LF, Phillips CM, Harrison PE, Menter A. The annual cost of psoriasis. J Am Acad Dermatol 1993; 28:422–425.
35. Lee GC, Weinstein GD. Comparative cost effectiveness of different treatments for psoriasis. In: Rajagopalan R, Sherertz EF, Aderson RT, eds. Care and Management of Skin Diseases: Life Quality and Economic Impact, New York: Marcel Dekker, Inc. 21:269–298.
36. Section contributed by Marcia Z. Weinstein, Ph.D.
37. Engel GL. The need for a new medical model: a challenge for biomedicine. Science 1977; 196:4286.
38. Baugham R, Sobel R. Psoriasis, stress, and strain. Arch Dermatol 1971; 103:599–605.
39. Arnetz BB, Fjellner B, Eneroth P, Kallner A. Stress and psoriasis: psychoendocrine and metabolic reactions in psoriatic patients during standardized stressor exposure. Psychosom Med 1985; 47:528–541.
40. Lazarus RS. Psychological Stress and the Coping Process. New York: McGraw Hill, 1966.
41. Weinstein MZ. Psoriasis-specific relaxation training/guided imagery as adjuvant treatment for intractable psoriasis. Doctoral dissertation, Nova University, 1988.